Covid-19: NAFDAC To Continue Hydroxychloroquine Clinical Trials, Says It Is Effective

Covid-19: NAFDAC To Continue Hydroxychloroquine Clinical Trials, Says It Is Effective




Oluwafemi _Fasoyin_ , Lagos

Despite the suspension of hydroxychloroquine clinical trials for the treatment of COVID-19 by the World Health Organisation The National Agency for Food and Drug Administration and Control says it will continue the trial.

NAFDAC Director-General, Prof Mojisola Adeyeye, disclosed this on Tuesday.

The DG disclosed that hydroxychloroquine had been effective in the treatment of COVID-19 patients, especially those at the “mild stage” of the virus and that there is data to prove.

She however stated that Nigeria would continue the trial since Hydroxychloroquine has been proved to work at a mild stage. So the potency depends on the severity of the disease in the patient’s body,” she said.

Adeyeye further disclosed that Lagos State had already begun hydroxychloroquine clinical trials, noted that depending on the speed of work, the clinical trials should conclude in three to four months.

“If medical doctors, research scientists, pharmacists, herbal experts work together, we should conclude the clinical trial in three to four months. The narrative might change afterwards but for now, we believe in hydroxychloroquine.” she said.

Post a Comment

0 Comments